Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule

Abstract Given that the last notified case of poliomyelitis due to wild poliovirus type 2 was in 1999, in 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) of the World Health Organization (WHO) recommended the withdrawal of the type 2 component of oral polio vaccine (OPV) and the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Arbo,Antonio, Falleiros-Arlant,Luiza Helena, López,Eduardo L., Brea del Castillo,José, Martínez de Cuellar,Celia, Moreno,Gabriela, Rolón,Roger, Cerda,Javier, Eguiazú,Salim
Lenguaje:English
Publicado: Sociedad Chilena de Infectología 2019
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182019000100083
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0716-10182019000100083
record_format dspace
spelling oai:scielo:S0716-101820190001000832019-04-23Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization ScheduleArbo,AntonioFalleiros-Arlant,Luiza HelenaLópez,Eduardo L.Brea del Castillo,JoséMartínez de Cuellar,CeliaMoreno,GabrielaRolón,RogerCerda,JavierEguiazú,SalimAbstract Given that the last notified case of poliomyelitis due to wild poliovirus type 2 was in 1999, in 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) of the World Health Organization (WHO) recommended the withdrawal of the type 2 component of oral polio vaccine (OPV) and the introduction of a bivalent OPV (bOPV) in all countries by 2016. WHO recommended also that the withdrawal should be preceded by the introduction of at least one dose of inactivated poliovirus vaccine (IPV) in routine immunization schedules. The introduction of IPV prior to the change of the bOPV in 2016 to trivalent OPV (tOPV) was based on the concept of ensuring that a substantial proportion of the population would be protected against type 2 polio after the removal of the type 2 OPV. However, the world's two producers of IPV (Bilthoven Biologicals and Sanofi) have faced problems in the production of this vaccine and therefore reported a reduction of the global supply of IPV. In response to the potential shortage of IPV, at a meeting held on March 10 2017, the SAGE and Technical Advisory Group (TAG) of the Pan American Health Organization (PAHO) urged the countries in the Latin American region to replace the routine administration of the full doses of inactivated polio vaccine (IPV-C) in the immunization schedule (administered by intramuscular route), administering a fraction of the full dose in two intradermal shots (IPV-f). The possibility of this strategy was analyzed by opinion leaders convened by the Paraguayan Society of Pediatrics with the support of the Latin American Society of Pediatric Infectious Diseases (SLIPE) and Latin American Association of Pediatrics (ALAPE). This document presents the results of the discussion.info:eu-repo/semantics/openAccessSociedad Chilena de InfectologíaRevista chilena de infectología v.36 n.1 20192019-02-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182019000100083en10.4067/S0716-10182019000100083
institution Scielo Chile
collection Scielo Chile
language English
description Abstract Given that the last notified case of poliomyelitis due to wild poliovirus type 2 was in 1999, in 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) of the World Health Organization (WHO) recommended the withdrawal of the type 2 component of oral polio vaccine (OPV) and the introduction of a bivalent OPV (bOPV) in all countries by 2016. WHO recommended also that the withdrawal should be preceded by the introduction of at least one dose of inactivated poliovirus vaccine (IPV) in routine immunization schedules. The introduction of IPV prior to the change of the bOPV in 2016 to trivalent OPV (tOPV) was based on the concept of ensuring that a substantial proportion of the population would be protected against type 2 polio after the removal of the type 2 OPV. However, the world's two producers of IPV (Bilthoven Biologicals and Sanofi) have faced problems in the production of this vaccine and therefore reported a reduction of the global supply of IPV. In response to the potential shortage of IPV, at a meeting held on March 10 2017, the SAGE and Technical Advisory Group (TAG) of the Pan American Health Organization (PAHO) urged the countries in the Latin American region to replace the routine administration of the full doses of inactivated polio vaccine (IPV-C) in the immunization schedule (administered by intramuscular route), administering a fraction of the full dose in two intradermal shots (IPV-f). The possibility of this strategy was analyzed by opinion leaders convened by the Paraguayan Society of Pediatrics with the support of the Latin American Society of Pediatric Infectious Diseases (SLIPE) and Latin American Association of Pediatrics (ALAPE). This document presents the results of the discussion.
author Arbo,Antonio
Falleiros-Arlant,Luiza Helena
López,Eduardo L.
Brea del Castillo,José
Martínez de Cuellar,Celia
Moreno,Gabriela
Rolón,Roger
Cerda,Javier
Eguiazú,Salim
spellingShingle Arbo,Antonio
Falleiros-Arlant,Luiza Helena
López,Eduardo L.
Brea del Castillo,José
Martínez de Cuellar,Celia
Moreno,Gabriela
Rolón,Roger
Cerda,Javier
Eguiazú,Salim
Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule
author_facet Arbo,Antonio
Falleiros-Arlant,Luiza Helena
López,Eduardo L.
Brea del Castillo,José
Martínez de Cuellar,Celia
Moreno,Gabriela
Rolón,Roger
Cerda,Javier
Eguiazú,Salim
author_sort Arbo,Antonio
title Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule
title_short Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule
title_full Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule
title_fullStr Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule
title_full_unstemmed Remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule
title_sort remarks on the possibility of introducing the fractionated dose of the inactivated poliomyelitis vaccine in the latin american child immunization schedule
publisher Sociedad Chilena de Infectología
publishDate 2019
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182019000100083
work_keys_str_mv AT arboantonio remarksonthepossibilityofintroducingthefractionateddoseoftheinactivatedpoliomyelitisvaccineinthelatinamericanchildimmunizationschedule
AT falleirosarlantluizahelena remarksonthepossibilityofintroducingthefractionateddoseoftheinactivatedpoliomyelitisvaccineinthelatinamericanchildimmunizationschedule
AT lopezeduardol remarksonthepossibilityofintroducingthefractionateddoseoftheinactivatedpoliomyelitisvaccineinthelatinamericanchildimmunizationschedule
AT breadelcastillojose remarksonthepossibilityofintroducingthefractionateddoseoftheinactivatedpoliomyelitisvaccineinthelatinamericanchildimmunizationschedule
AT martinezdecuellarcelia remarksonthepossibilityofintroducingthefractionateddoseoftheinactivatedpoliomyelitisvaccineinthelatinamericanchildimmunizationschedule
AT morenogabriela remarksonthepossibilityofintroducingthefractionateddoseoftheinactivatedpoliomyelitisvaccineinthelatinamericanchildimmunizationschedule
AT rolonroger remarksonthepossibilityofintroducingthefractionateddoseoftheinactivatedpoliomyelitisvaccineinthelatinamericanchildimmunizationschedule
AT cerdajavier remarksonthepossibilityofintroducingthefractionateddoseoftheinactivatedpoliomyelitisvaccineinthelatinamericanchildimmunizationschedule
AT eguiazusalim remarksonthepossibilityofintroducingthefractionateddoseoftheinactivatedpoliomyelitisvaccineinthelatinamericanchildimmunizationschedule
_version_ 1718440482865938432